Cardio Diagnostics Holdings, Inc. CDIO

CDIO Company Overview

Cardio Diagnostics Holdings, Inc. is a U.S.-based precision cardiovascular medicine company focused on integrating artificial intelligence, epigenetics, and clinical diagnostics to improve the detection and management of cardiovascular disease. The company operates within the healthcare diagnostics, biotechnology, and digital health industries, with an emphasis on blood-based cardiovascular testing and personalized risk assessment. Its primary commercial offerings include epigenetic and genetic tests intended to assist clinicians in identifying coronary heart disease risk and supporting disease management strategies.

The company’s principal revenue drivers are laboratory-developed diagnostic tests, clinical partnerships, and commercialization of proprietary cardiovascular risk assessment technologies. Key customer segments include healthcare providers, physician groups, hospitals, and preventative medicine practices. Cardio Diagnostics positions itself as a precision medicine company leveraging machine learning-enabled biomarker analysis to deliver non-invasive cardiovascular diagnostics. The company was founded in 2017 and later became publicly traded through a merger transaction involving a special purpose acquisition company. Public disclosures in SEC filings and investor materials indicate that the company has evolved from a research-oriented diagnostics developer into a commercially focused cardiovascular testing enterprise centered on AI-driven precision medicine.